nkt2152
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2021 (NCT05119335)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Colorectal Neoplasms · Phase 2
- Hypoxia · Phase 1/Phase 2
- Hypoxia-Inducible Factor 1 · Phase 1/Phase 2
- Kidney Diseases · Phase 2
- Kidney Neoplasms · Phase 2
- Neoplasms · Phase 2
- Neoplasms by Site · Phase 2
- Neoplasms, Glandular and Epithelial · Phase 2
- Sarcoma, Clear Cell · Phase 1/Phase 2
- Urogenital Neoplasms · Phase 2
- Urologic Diseases · Phase 2
- Urologic Neoplasms · Phase 2
Mechanism of action
EPAS1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05935748 | Phase 2 | Jul 28, 2023 | NiKang Therapeutics, Inc., Pfizer |
| NCT05119335 | Phase 1/Phase 2 (Phase 2) | Oct 26, 2021 | NiKang Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NiKang Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2021 |
| Pfizer | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1